Key result
Delaying angiography to 24-72 hours shows no mortality difference vs. <24 hours in NSTE-ACS.
Why the study?
Current guidelines emphasize early invasive assessment in NSTE-ACS patients, especially high-risk, but supporting scientific evidence is limited.
Does early coronary angiography (<24 hours) improve long-term clinical outcomes compared to delayed angiography (24-72 hours) in patients with NSTE-ACS?
Cohort (n=34,666)
Yes
Does early coronary angiography (<24 hours) improve long-term clinical outcomes compared to delayed angiography (24-72 hours) in patients with NSTE-ACS?
In a large nationwide registry of NSTE-ACS patients, an early invasive strategy (<24 hours) did not provide a prognostic benefit compared to a 24-72 hour window, challenging current guideline recommendations for early invasive assessment in high-risk patients.
Answers are grounded in this paper and cite their sources.
Should not yet change NSTE-ACS angiography timing; leaves open optimal window for randomized trials.
BACKGROUND: Current guidelines stress the importance of early invasive assessment of patients with non-ST-elevation acute coronary syndrome (NSTE-ACS), in particular those at high risk. However, supporting scientific evidence is limited. AIMS: We aimed to investigate the prognostic impact of the timing of coronary angiography in a large cohort of NSTE-ACS patients. METHODS: We performed a retrospective analysis including 34,666 NSTE-ACS patients registered from 2013 to 2018 in the SWEDEHEART registry. The prognostic implications of the timing of coronary angiography on a continuous scale and within <24 vs 24-72 hours were assessed using Cox regression analyses. RESULTS: The median time interval from admission to invasive assessment was 32.8 (25th, 75th percentiles 20.4-63.8) hours. There was no apparent time window within 96 hours from admission that provided prognostic benefit. Coronary angiography within 24-72 hours (vs <24 hours) was not associated with worse outcome overall (all-cause mortality: hazard ratio 1.01, 95% confidence interval [CI] 0.92-1.11; major adverse events: hazard ratio 1.04, 95% CI: 0.98-1.12). Interaction analyses indicated a greater relative benefit of coronary angiography <24 hours in some lower-risk groups (women, non-diabetics, patients with minor troponin elevation) but neutral effects in higher-risk groups (defined by age or the GRACE 2.0 score). CONCLUSIONS: These Swedish data do not provide support for an early invasive strategy in NSTE-ACS, especially in high-risk patients. Our results suggest that the timing of invasive assessment should rather be based on individualised decisions integrating symptoms and risk panorama than on strictly defined time intervals.
No takes yet. Share an insight, caveat, or question.
Eggers et al. (2022) conducted a cohort in non-ST-elevation acute coronary syndrome (NSTE-ACS) (n=34,666). Coronary angiography within 24-72 hours vs. Coronary angiography <24 hours was evaluated on all-cause mortality (HR 1.01, 95% CI 0.92-1.11). Coronary angiography within 24-72 hours compared to <24 hours was not associated with worse all-cause mortality in patients with NSTE-ACS.
Synapse has enriched 10 related papers. Consider them for comparative context: